通过使用CoVex的假设驱动系统医学确定可能用于治疗COVID-19的可重新利用药物和药物靶点。
Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.
作者信息
Matschinske Julian, Salgado-Albarrán Marisol, Sadegh Sepideh, Bongiovanni Dario, Baumbach Jan, Blumenthal David B
机构信息
Chair of Experimental Bioinformatics, Technical University of Munich, Freising, Germany.
Natural Sciences Department, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico City, Mexico.
出版信息
Assay Drug Dev Technol. 2020 Nov/Dec;18(8):348-355. doi: 10.1089/adt.2020.1010. Epub 2020 Nov 6.
Abstract
in silico
摘要
计算机模拟
相似文献
1
Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.通过使用CoVex的假设驱动系统医学确定可能用于治疗COVID-19的可重新利用药物和药物靶点。
Assay Drug Dev Technol. 2020 Nov/Dec;18(8):348-355. doi: 10.1089/adt.2020.1010. Epub 2020 Nov 6.
2
SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.SAveRUNNER：一种基于网络的药物重定位算法及其在 COVID-19 中的应用。
PLoS Comput Biol. 2021 Feb 5;17(2):e1008686. doi: 10.1371/journal.pcbi.1008686. eCollection 2021 Feb.
3
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.探索 SARS-CoV-2 病毒-宿主-药物相互作用组以进行药物再利用。
Nat Commun. 2020 Jul 14;11(1):3518. doi: 10.1038/s41467-020-17189-2.
4
Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19.生物信息学和系统生物学分析表明，PMID26394986-Compound-10 可能成为治疗 COVID-19 的潜在再利用药物。
J Biomol Struct Dyn. 2024 Sep;42(15):7972-7985. doi: 10.1080/07391102.2023.2242500. Epub 2023 Aug 3.
5
Advances in the computational landscape for repurposed drugs against COVID-19.针对 COVID-19 的再利用药物的计算领域进展。
Drug Discov Today. 2021 Dec;26(12):2800-2815. doi: 10.1016/j.drudis.2021.07.026. Epub 2021 Jul 30.
6
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.采用整合生物信息学方法，鉴定靶向 SARS-CoV-1 感染的宿主转录组可再利用药物，并通过 SARS-CoV-2 感染进行验证。
PLoS One. 2022 Apr 7;17(4):e0266124. doi: 10.1371/journal.pone.0266124. eCollection 2022.
7
Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.肺上皮细胞的综合转录组学分析及 COVID-19 再利用药物候选物的鉴定。
Eur J Pharmacol. 2020 Nov 15;887:173594. doi: 10.1016/j.ejphar.2020.173594. Epub 2020 Sep 22.
8
Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.基于蛋白质-蛋白质相互作用网络分析的新型冠状病毒疾病治疗候选药物的再利用。
BMC Biotechnol. 2021 Mar 12;21(1):22. doi: 10.1186/s12896-021-00680-z.
9
Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.针对 COVID-19 的计算机药物研发新兴策略：挑战与机遇。
Eur J Pharm Sci. 2020 Dec 1;155:105522. doi: 10.1016/j.ejps.2020.105522. Epub 2020 Aug 20.
10
Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach.通过计算机模拟方法为 COVID-19 治疗药物研发寻找用途的新途径。
Drug Dev Res. 2021 May;82(3):374-392. doi: 10.1002/ddr.21757. Epub 2020 Nov 10.
引用本文的文献
1
Recent advances and future directions on GLA-producing organisms.产γ-亚麻酸（GLA）生物的最新进展与未来方向。
Front Bioeng Biotechnol. 2025 Jul 9;13:1567840. doi: 10.3389/fbioe.2025.1567840. eCollection 2025.
2
Network-based approaches for modeling disease regulation and progression.基于网络的疾病调控与进展建模方法。
Comput Struct Biotechnol J. 2022 Dec 16;21:780-795. doi: 10.1016/j.csbj.2022.12.022. eCollection 2023.
3
CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.CTCFL 调控 PI3K-Akt 通路，是卵巢癌个体化治疗的靶点。
NPJ Syst Biol Appl. 2022 Feb 7;8(1):5. doi: 10.1038/s41540-022-00214-z.
4
Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches.宿主导向抗病毒疗法的靶点发现：蛋白质组学方法的应用
mSystems. 2021 Oct 26;6(5):e0038821. doi: 10.1128/mSystems.00388-21. Epub 2021 Sep 14.
5
An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染诊断与治疗新方法的最新进展。
Cell Biosci. 2021 Aug 22;11(1):164. doi: 10.1186/s13578-021-00674-6.
6
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype.SARS-CoV-2 感染与促血栓形成的血小板表型有关。
Cell Death Dis. 2021 Jan 5;12(1):50. doi: 10.1038/s41419-020-03333-9.
本文引用的文献
1
Network medicine framework for identifying drug-repurposing opportunities for COVID-19.用于识别新冠病毒药物再利用机会的网络医学框架。
Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2025581118.
2
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.探索 SARS-CoV-2 病毒-宿主-药物相互作用组以进行药物再利用。
Nat Commun. 2020 Jul 14;11(1):3518. doi: 10.1038/s41467-020-17189-2.
3
New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.对 SARS-CoV-2 感染呼吸系统以外的损伤的新认识。
Biomed Pharmacother. 2020 Jul;127:110195. doi: 10.1016/j.biopha.2020.110195. Epub 2020 Apr 28.
4
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
5
COVID-19 cytokine storm: the interplay between inflammation and coagulation.新型冠状病毒肺炎细胞因子风暴：炎症与凝血之间的相互作用
Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.
6
Anticoagulation in COVID-19.新型冠状病毒肺炎中的抗凝治疗
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):260-261. doi: 10.1093/ehjcvp/pvaa036.
7
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
8
Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands.新型冠状病毒肺炎相关血栓栓塞性并发症的诊断、预防和治疗：荷兰国家公共卫生研究所报告。
Radiology. 2020 Oct;297(1):E216-E222. doi: 10.1148/radiol.2020201629. Epub 2020 Apr 23.
9
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.基于网络的2019新型冠状病毒（2019-nCoV/SARS-CoV-2）药物重新利用研究
Cell Discov. 2020 Mar 16;6:14. doi: 10.1038/s41421-020-0153-3. eCollection 2020.
10
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
Zotero 插件